Moyamoya disease diagnosis and treatment
Moyamoya disease diagnosis and treatment is a research topic within Rheumatology. Science Explorer counts 12k research works in it since 1950. 11.8% of them reached the world's top 10% most cited for their field and year.
This cluster of papers represents current research on Moyamoya disease and syndrome, focusing on genetic susceptibility (RNF213 gene), revascularization surgery, neurological complications, and epidemiological features. It covers a wide range of topics including the clinical features, treatment outcomes, genetic factors, and long-term prognosis of Moyamoya disease. The research also explores the pathophysiology, neurocognitive effects, and vascular development associated with this cerebrovascular disease.
- Moyamoya Disease
- RNF213 Gene
- Cerebrovascular Disease
- Revascularization Surgery
- Genetic Susceptibility
- Neurological Complications
- Pediatric Patients
- Cerebral Hyperperfusion
- Vascular Development
- Epidemiological Features
- Research works
- 12k fractional, since 1950
- In the world top 10%
- 1.4k per year above
- Top-10% rate
- 11.8% share of its works in the world top 10%
- Growth, 2013–17 → 2018–22
- +20% the tick is no change
This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.
Which countries lead Moyamoya disease diagnosis and treatment research?
By volume, the United States and China publish the most (465 and 460 works in 2022–2025).
By volume, 2022–2025
- 1 United States 465 works
- 2 China 460 works
- 3 Japan 280 works
- 4 India 130 works
- 5 South Korea 93 works
- 6 Germany 60 works
- 7 Italy 56 works
- 8 Brazil 51 works
- 9 France 50 works
- 10 Türkiye 45 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead Moyamoya disease diagnosis and treatment research?
By volume in 2022–2025, Capital Medical University publishes the most Moyamoya disease diagnosis and treatment research, followed by Neurological Surgery and Beijing Tian Tan Hospital.
By volume, 2022–2025
- 1 Capital Medical UniversityChina 23 works
- 2 Neurological SurgeryUnited States 14 works
- 3 Beijing Tian Tan HospitalChina 11 works
- 4 Chinese PLA General HospitalChina 11 works
- 5 Hokkaido UniversityJapan 10 works
- 6 All India Institute of Medical SciencesIndia 9 works
- 7 National Cerebral and Cardiovascular CenterJapan 8 works
- 8 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 8 works
- 9 Harvard UniversityUnited States 7 works
- 10 First Affiliated Hospital of Zhengzhou UniversityChina 7 works
Who are the leading researchers in Moyamoya disease diagnosis and treatment?
The most-cited researchers publishing on Moyamoya disease diagnosis and treatment include Charles G. Drake.
- 1 Charles G. Drake United States 2.4k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is Moyamoya disease diagnosis and treatment research done?
The largest centres of Moyamoya disease diagnosis and treatment research in 2022–2025 are Beijing (China), Tokyo (Japan), Seoul (South Korea) and Shanghai (China). Among places with at least 20 works in it, it is an unusually large share of all research in Sapporo and Osaka.
Largest cities, 2022–2025
Where it is the local speciality
- SapporoJP · 22.1 works15×
- OsakaJP · 20.2 works5.9×
Location quotient: how much more of its research is in Moyamoya disease diagnosis and treatment than the world average.
Where is the best place to study Moyamoya disease diagnosis and treatment?
Among universities, judged by research, Capital Medical University, Hokkaido University and Chinese Academy of Medical Sciences & Peking Union Medical College score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.
| # | University | Score | Top 10% | Specialisation | Works | Growth |
|---|---|---|---|---|---|---|
| 1 | Capital Medical UniversityChina | 70.1 | 9.2% | 19.0× | 23 | +67.7% |
| 2 | Hokkaido UniversityJapan | 53.1 | 13.2% | 11.5× | 10 | -13.0% |
| 3 | Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina | 42.0 | 26.7% | 4.0× | 8 | +39.9% |
| 4 | All India Institute of Medical SciencesIndia | 13.3 | 0.0% | 6.8× | 9 | -16.6% |
Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.
Is Moyamoya disease diagnosis and treatment research growing?
Output in 2018–2022 was 20% higher than in 2013–2017, peaking in 2025. The fastest-growing topics are Moyamoya disease diagnosis and treatment.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.